ArticleInfluenza and other respiratory viruses2025
In-Hospital Mortality and Severe Respiratory and Renal Outcomes-A Territory-Wide Comparison Between RSV and Influenza.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Global Burden of Human Metapneumovirus in High-Risk Adults: A Systematic Literature Review and Meta-Analysis.Journal of epidemiology and global health · 2026Pooled it
- Clinical Impact of RSV Vaccination in Hemodialysis Patients: Real-World Evidence on Hospitalization Risk and the Role of Chronic Lung Disease.Advances in respiratory medicine · 2026Article
- In-Hospital Mortality and Severe Respiratory and Renal Outcomes-A Territory-Wide Comparison Between RSV and Influenza.Influenza and other respiratory viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionRespiratory syncytial virus (RSV) and influenza virus are important respiratory viruses. Although RSV vaccines have been developed and recommended for patients aged ≥ 60, there is limited data on the clinical impact among the non-elderly population. It is also important to know the patient subgroups that are at risk of complications from RSV infections.
methodsWe conducted a territory-wide retrospective study on adults hospitalized for RSV or influenza virus infection between 1/1/2016 and 6/30/2023 in Hong Kong. The in-patient mortality, severe respiratory failure (SRF), secondary bacterial pneumonia, and acute kidney injury (AKI) were compared. Subgroup analyses were performed in different age groups. The risk factors for mortality and serious respiratory outcomes were assessed.
resultsA total of 41,206 and 3565 patients were hospitalized for influenza and RSV infections. Patients with RSV infection showed a significantly higher risk of in-patient mortality, SRF, secondary bacterial pneumonia, and AKI compared with those with influenza (p < 0.001, for all), and the results were consistent for patients aged ≥ 60, < 60, and 50-59. End-stage kidney disease requiring real replacement therapy was an independent risk factor for in-patient mortality and serious respiratory outcomes in RSV infection across different age groups (p < 0.001, for all).
conclusionsAdults hospitalized for RSV infection were associated with a significantly increased risk of in-patient mortality and adverse respiratory and kidney outcomes than those with influenza. The findings are consistent across various age groups, and the results call for an update on RSV vaccination recommendations in adults, especially for vulnerable subgroups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.